A recent narrative review published in Microorganisms (MDPI, 2025) evaluates the role of Darolac® (Oralis SB®), a multi-strain probiotic formulation, and highlights its potential as a science-backed, microbiome-friendly adjunct in oral health management.
From antisepsis to microbiome balance
The oral cavity is one of the most diverse microbial ecosystems in the human body. Oral health is not defined by the absence of microorganisms but by the stability and resilience of the microbial community. Dysbiosis – rather than infection alone – is increasingly recognized as a key driver of gingival inflammation, periodontal disease, and mucosal imbalance.
Conventional antiseptic mouthwashes remain effective for short-term bacterial control; however, long-term use may disrupt commensal microbial populations; affect taste and oral comfort; compromise microbiome resilience.
This has heightened interest in probiotic and postbiotic strategies that support physiological microbial balance rather than indiscriminate microbial eradication.
Darolac® (Oralis SB®): a rationally designed probiotic formulation
Darolac® is a well-characterised probiotic formulation combining bacterial and yeast strains with established safety profiles and documented functional properties: Lactobacillus acidophilus Rosell®-52, Lactobacillus rhamnosus Rosell®-11, Bifidobacterium longum Rosell®-175, Saccharomyces boulardii CNCM I-1079.
The formulation has been developed to support:
- Competitive exclusion of oral pathogens
- Maintenance of mucosal barrier integrity
- Modulation of local immune responses
- Overall oral microbiome homeostasis
Evidence overview: key insights from the MDPI review
The narrative review synthesises clinical and mechanistic data assessing Darolac® in oral health applications. Key findings include:
Support for periodontal health
Clinical observations demonstrate improvements in gingival and periodontal parameters when Darolac® is used alongside standard oral hygiene practices.
Microbiome-centric mechanism of action
Rather than acting as a broad antimicrobial, Darolac® promotes a favourable shift in oral microbial composition, supporting commensal species and limiting dysbiotic overgrowth.
Comparable outcomes to antiseptic mouthwashes
Across several clinical endpoints, probiotic intervention achieved outcomes comparable to those of chlorhexidine-based solutions, without the commonly reported adverse effects associated with chlorhexidine.
Suitability for long-term use
The probiotic approach demonstrated a favourable tolerability profile, supporting its role in sustained oral care regimens.
Conclusion
The MDPI review underscores a fundamental shift in oral care science: health is supported by microbial balance, not by microbial elimination. Darolac® (Oralis SB®) exemplifies a next-generation probiotic approach that integrates microbiome science with clinical relevance, offering a well-tolerated, evidence-based adjunct for oral health maintenance.
As microbiome research continues to inform product development across nutraceutical and cosmetic categories, probiotic oral care represents a strategically important and scientifically credible area of innovation.
Source:
Blais, L., Auclair-Ouellet, N., Tremblay, A., & Binda, S. (2025). Effect of the Darolac® (Oralis SB®) Probiotic Formulation on Oral Health: A Narrative Review. Microorganisms, 13(2), 408. https://doi.org/10.3390/microorganisms13020408
